Latest Commercialization News

Argent BioPharma reports strategic cost-cutting moves including facility closures and delisting from the LSE, while securing German distribution approval and raising significant capital to support its drug pipeline.

Horseshoe Metals has broadened its Horseshoe Lights project area and entered a strategic agreement with Melody Gold to process gold surface materials, advancing its copper-gold development plans in Western Australia.

Spenda Limited has reported a record-breaking quarter with cash receipts soaring 160% year-on-year and payment volumes more than doubling, signaling strong momentum as it advances toward profitability.

Micro-X announces a strategic pivot towards medical imaging, anchored by a $25 million US government contract to develop a portable Full Body CT scanner, while discontinuing its Argus security operations to streamline costs.

Advanced Health Intelligence Ltd (AHI) has secured USD 4 million in convertible debt funding and launched two new commercial partnerships in Canada and the UK, marking significant progress despite its ongoing ASX trading suspension.

Heavy Minerals Limited advances steadily on its Port Gregory Garnet Project, with the Pre-Feasibility Study nearing completion and critical permitting and sales groundwork underway.

High Peak Royalties reported robust cash receipts and successfully repaid its Macquarie Bank facility in the December 2024 quarter, while advancing its geothermal exploration strategy in South Australia.

Nanoveu Limited reports strong momentum in its EyeFly3D technology with a significant purchase order and launches an AI-powered app, while advancing its strategic acquisition of semiconductor innovator EMASS.

Cadoux Limited reports significant progress in its high purity alumina and Minhub rare earths projects, alongside robust environmental, social, and governance initiatives.

Recce Pharmaceuticals has gained key regulatory and ethics approvals for its Phase 3 clinical trial in Indonesia and completed patient dosing for its Phase II trial, while securing a substantial A$6.75 million R&D tax rebate to bolster its financial position.

Cardiex has kicked off deliveries of its CONNEQT Pulse arterial health monitors in the U.S., reporting strong preorder momentum and a 150% sales increase in December. The company’s strategic operational shifts and pharma partnerships set the stage for sustained growth in 2025.

Cardiex Limited reported a $2.94 million cash outflow for Q2 FY2025 but bolstered its balance sheet with a $3.25 million placement. The company has begun delivering its CONNEQT Pulse units, signaling a new revenue stream and ongoing R&D investment.